SG11201705924RA - CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> - Google Patents
CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>Info
- Publication number
- SG11201705924RA SG11201705924RA SG11201705924RA SG11201705924RA SG11201705924RA SG 11201705924R A SG11201705924R A SG 11201705924RA SG 11201705924R A SG11201705924R A SG 11201705924RA SG 11201705924R A SG11201705924R A SG 11201705924RA SG 11201705924R A SG11201705924R A SG 11201705924RA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline forms
- crystalline
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developing Agents For Electrophotography (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Removal Of Specific Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110449P | 2015-01-30 | 2015-01-30 | |
| PCT/US2016/015829 WO2016123574A1 (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705924RA true SG11201705924RA (en) | 2017-08-30 |
Family
ID=56544441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101979TA SG10202101979TA (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
| SG11201705924RA SG11201705924RA (en) | 2015-01-30 | 2016-01-29 | CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101979TA SG10202101979TA (en) | 2015-01-30 | 2016-01-29 | Crystalline forms of c21h22ci2n4o2 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9676746B2 (es) |
| EP (1) | EP3250562A4 (es) |
| JP (4) | JP7258460B2 (es) |
| CN (2) | CN107406413A (es) |
| AU (4) | AU2016211246B2 (es) |
| CA (2) | CA3218488A1 (es) |
| HK (1) | HK1244274A1 (es) |
| MX (1) | MX2017009696A (es) |
| NZ (2) | NZ734041A (es) |
| SG (2) | SG10202101979TA (es) |
| WO (1) | WO2016123574A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016211246B2 (en) | 2015-01-30 | 2020-08-27 | Biomed Valley Discoveries, Inc. | Crystalline forms of C21H22CI2N4O2 |
| CN107405345A (zh) * | 2016-01-27 | 2017-11-28 | 江苏恒瑞医药股份有限公司 | 一种含有喹啉衍生物或其盐的药物组合物的制备方法 |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| WO2021102279A1 (en) * | 2019-11-20 | 2021-05-27 | University Of Kentucky Research Foundation | Anti-cancer compositions and methods |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| AU2023238106A1 (en) * | 2022-03-24 | 2024-09-26 | Biomed Valley Discoveries, Inc. | Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| WO1987002672A1 (en) | 1985-10-23 | 1987-05-07 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| WO1990015816A1 (en) | 1989-06-16 | 1990-12-27 | The Upjohn Company | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| DK0614463T3 (da) | 1991-11-22 | 2003-03-31 | Alcon Lab Inc | Angiostatiske steroider |
| NZ514583A (en) | 2000-02-05 | 2004-05-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of ERK |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| AU2005245885B2 (en) | 2004-05-14 | 2011-01-20 | Vertex Pharmaceuticals, Incorporated | Pyrrole compounds as inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| PT2091910E (pt) | 2006-12-06 | 2014-11-18 | Conatus Pharmaceuticals Inc | Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico |
| US9346800B2 (en) * | 2012-09-18 | 2016-05-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| AU2016211246B2 (en) | 2015-01-30 | 2020-08-27 | Biomed Valley Discoveries, Inc. | Crystalline forms of C21H22CI2N4O2 |
-
2016
- 2016-01-29 AU AU2016211246A patent/AU2016211246B2/en active Active
- 2016-01-29 CN CN201680013774.5A patent/CN107406413A/zh active Pending
- 2016-01-29 JP JP2017539596A patent/JP7258460B2/ja active Active
- 2016-01-29 SG SG10202101979TA patent/SG10202101979TA/en unknown
- 2016-01-29 WO PCT/US2016/015829 patent/WO2016123574A1/en active Application Filing
- 2016-01-29 US US15/011,377 patent/US9676746B2/en active Active
- 2016-01-29 CN CN202310821608.XA patent/CN116854662A/zh active Pending
- 2016-01-29 NZ NZ734041A patent/NZ734041A/en unknown
- 2016-01-29 EP EP16744240.9A patent/EP3250562A4/en active Pending
- 2016-01-29 NZ NZ772411A patent/NZ772411A/en unknown
- 2016-01-29 SG SG11201705924RA patent/SG11201705924RA/en unknown
- 2016-01-29 CA CA3218488A patent/CA3218488A1/en active Pending
- 2016-01-29 MX MX2017009696A patent/MX2017009696A/es unknown
- 2016-01-29 CA CA2975048A patent/CA2975048C/en active Active
-
2017
- 2017-05-17 US US15/598,181 patent/US10183927B2/en active Active
-
2018
- 2018-03-16 HK HK18103713.0A patent/HK1244274A1/zh unknown
- 2018-12-20 US US16/227,820 patent/US10738027B2/en active Active
-
2020
- 2020-03-31 JP JP2020063198A patent/JP2020100674A/ja active Pending
- 2020-07-07 US US16/922,365 patent/US11390600B2/en active Active
- 2020-10-20 AU AU2020257041A patent/AU2020257041C1/en active Active
-
2021
- 2021-12-01 JP JP2021195403A patent/JP2022033866A/ja active Pending
-
2022
- 2022-06-16 US US17/842,632 patent/US20220324832A1/en active Pending
- 2022-09-05 AU AU2022228084A patent/AU2022228084B2/en active Active
-
2023
- 2023-05-17 JP JP2023081553A patent/JP2023096080A/ja active Pending
- 2023-10-25 AU AU2023254937A patent/AU2023254937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273730A (en) | crystalline forms | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane | |
| SG11201705924RA (en) | CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb> | |
| IL259998A (en) | Polymorphic crystalline forms of obeticholic acid | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| SI3577125T1 (sl) | Kristalinične oblike tenofovirijevega alafenamida | |
| HK1255112A1 (zh) | 吉西他濱的晶型 | |
| HK1247125A1 (zh) | 結晶化合物 | |
| PL3113773T3 (pl) | Krystaliczne postaci grapiprantu | |
| PL3529236T3 (pl) | Krystaliczne formy erawacykliny | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| IL265445A (en) | crystalline forms | |
| HK1252842A1 (zh) | 噻吩並嘧啶化合物的結晶形式 | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| IL269792B (en) | Crystalline forms of (s)–apoxolner | |
| HK1255148A1 (zh) | 結晶形式 | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| ZA201902553B (en) | Crystalline forms | |
| GB201715010D0 (en) | Crystalline forms | |
| GB201704789D0 (en) | Crystalline compounds | |
| GB201604759D0 (en) | Crystalline compounds |